Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Blood (2025) 146 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2025-2152

Published: 2025

Journal Articles

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Blood (2025) 146 (Supplement 1): 685.

https://doi.org/10.1182/blood-2025-685

Published: 2025

Journal Articles

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 7465.

https://doi.org/10.1182/blood-2025-7465

Published: 2025

Journal Articles

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Blood (2025) 146 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2025-5821

Published: 2025

Journal Articles

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Blood (2025) 146 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2025-1030

Published: 2025

Journal Articles

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

Sofie-Katrin Kadel, Alexander Leipold, Philipp Weis, Tobias Krammer, Lukas Scheller, Julia Mersi, Nazia Afrin, Johannes Waldschmidt, K. Martin Kortüm, Hermann Einsele, Antoine-Emmanuel Saliba, Leo Rasche

Blood (2025) 146 (Supplement 1): 5698.

https://doi.org/10.1182/blood-2025-5698

Published: 2025

Journal Articles

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler, Erin Meermeier, Antonia Schach, Vera Thiel, Tim Wagner, Niklas Kehl, Stefanie Huhn, Alexander Brobeil, Carsten Müller-Tidow, P. Leif Bergsagel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Marta Chesi, Marc Raab, Niels Weinhold, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2025-3951

Published: 2025

Journal Articles

NQO1 modulates CD38 surface expression in multiple myeloma

Seungbin Han, Christina Verbruggen, Silvia Nerreter, Umair Munawar, Shilpa Kurian, Emma Besant, Ann-Sophie Hainold, Cornelia Vogt, Xiang Zhou, Hermann Einsele, Leo Rasche, Markus Sauer, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 5718.

https://doi.org/10.1182/blood-2025-5718

Published: 2025

Journal Articles

Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms

Vivien Reinecke, Kereshmeh Tasbihi, Maike Büttner-Herold, Johannes Berges, Christopher Lischer, Katrin Bitterer, Simon Voelkl, Frederik Graw, Pascal Lukas, Matthias Peipp, Leo Rasche, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2025) 146 (Supplement 1): 5711.

https://doi.org/10.1182/blood-2025-5711

Published: 2025

Journal Articles

Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells

Umair Munawar, Alexander Leipold, Silvia Nerreter, Seungbin Han, Shilpa Kurian, Emma Besant, Nina Rein, Max Koeppel, Johanna Lehmann, Xiang Zhou, Hermann Einsele, Leo Rasche, Emmanuel Saliba, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2025-5701

Published: 2025

Journal Articles

Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies

Julia Weingart, Patrick Eiring, Umair Munawar, Seungbin Han, Christina Verbruggen, Silvia Nerreter, Shilpa Kurian, Max Steinhardt, Leo Rasche, Hermann Einsele, Johannes Waldschmidt, K. Martin Kortüm, Markus Sauer

Blood (2025) 146 (Supplement 1): 4343.

https://doi.org/10.1182/blood-2025-4343

Published: 2025

Journal Articles

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

Blood (2025) 146 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2025-3938

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Blood (2025) 146 (Supplement 1): 809.

https://doi.org/10.1182/blood-2025-809

Published: 2025

Journal Articles

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Blood (2025) 146 (Supplement 1): 802.

https://doi.org/10.1182/blood-2025-802

Published: 2025

Journal Articles

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Blood (2025) 146 (Supplement 1): 6812.

https://doi.org/10.1182/blood-2025-6812

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma

Xiang Zhou, Umair Munawar, Shilpa Kurian, Seungbin Han, Mara John, Hanna Fischer, Silvia Nerreter, Lenka Besse, Andrej Besse, Christoph Driessen, Marc Schmalzing, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2025-2174

Published: 2025

Journal Articles

Upregulation of BCMA expression by selinexor

Christina Verbruggen, Umair Munawar, Seungbin Han, Julia Mersi, Emma Besant, Shilpa Kurian, Silvia Nerreter, Nina Rein, Johanna Lehmann, Max Koeppel, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 6102.

https://doi.org/10.1182/blood-2025-6102

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

NQO1 modulates CD38 surface expression in multiple myeloma

Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms

Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells

Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma

Upregulation of BCMA expression by selinexor

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only